Inspyr Therapeutics appoints Richard Buller to its board
Dr. Buller has over 25 years of experience leading the development of novel oncology products, resulting in 15 regulatory submissions for 8 oncology drug products as well as 2 premarketing approvals for companion diagnostics.
In his most recent positions, Dr. Buller served initially as Vice President of Translational Oncology, adding a brief role as Interim Head of Late-Stage Clinical Development, and then became Pfizer’s Head of Oncology Clinical Development.
Previously, he was Vice President, Translational Medicine for Exelixis and was a member of the Joint Development Committees with partners Bristol Myers Squibb and Sanofi Aventis.
Earlier, he was Director, Oncology Medicine Development Center at GSK. Dr. Buller also has 13 years of direct experience in clinical and laboratory oncology research, holding positions of increasing responsibility including 10 years as Division Director of Gynecologic Oncology at the University of Iowa Hospitals and Clinics.
He has been recognized as one of America’s Top Physicians on multiple occasions.
Dr. Buller was awarded a Doctor of Medicine from Baylor College of Medicine, with honors.
He earned a Bachelor of Science from the University of California Los Angeles (UCLA), graduating summa cum laude with honors in chemistry, where he was selected to receive the 2016 UCLA Chemistry and Biochemistry Alumni Award. ■
LATEST MOVES FROM California
- Twitter appoints Patrick Pichette to board
- eBay appoints two to board
- Cisco executive chairman John Chambers to step down
- Wesco Aircraft Holdings appoints Kerry A. Shiba as CFO
- Achaogen appoints Liz Bhatt as CBO
More inside POST
Valeant earned $1.05 per share in Q2 Earnings